Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sutro Biopharma Inc (Sutro Biopharma) is a clinical-stage oncology company that carries out the discovery and development of cancer therapeutics. The company provides antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immune-oncology therapies and vaccines through its XpressCF and XpressCF+ platforms. The company’s product pipeline includes STRO-002 and luvelta targeting ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer and GLlS2 pediatric acute myeloid leukemia; and STRO-004 for solid tumors. It is also developing partner programs such as VAX-24 and VAX-31 for invasive pneumococcal disease; MK-1484 which treats metastatic solid tumors; and STRO-003 targeting solid tumor and hematological cancers. It works in collaboration with pharmaceutical and biotechnology companies such as Merck & Co. Inc. and Astellas Pharma Inc. Sutro Biopharma is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
111 Oyster Point Blvd., South San Francisco, California, 94080
Website
www.sutrobio.com
Telephone
1 650 3928412
No of Employees
302
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
STRO (NASD)
Revenue (2022)
$153.7M
126.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
10.4%
(2022 vs 2021)
Market Cap*
$321.3M
Net Profit Margin (2022)
XYZ
60.5%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | XpressCF |
| Sutro-Led Programs: | XpressCF+ |
| STRO-002 and Luvelta: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into a manufacturing rights agreement with Vaxcyte under which Vaxcyte obtained exclusive rights to independently or through certain third parties, develop, improve, and manufacture cell-free extract. |
| 2023 | Contracts/Agreements | In June, the company and Blackstone entered into a royalty financing collaboration agreement under which funds managed by Blackstone Life Sciences will provide US$140 million upfront with up to an additional US$250 million in future payments triggered at various return thresholds. |
| 2023 | Plans/Strategy | In March, the company announced its plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer. |
Competitor Comparison
| Key Parameters | Sutro Biopharma Inc | Johnson & Johnson | ADC Therapeutics SA | Mersana Therapeutics Inc | Aprea Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | South San Francisco | New Brunswick | Epalinges | Cambridge | Doylestown |
| State/Province | California | New Jersey | - | Massachusetts | Pennsylvania |
| No. of Employees | 302 | 131,900 | 273 | 123 | 7 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Connie Matsui | Chairman | Executive Board | 2019 | 70 |
| William J. Newell | Chief Executive Officer; Director | Executive Board | 2009 | 66 |
| Edward Albini | Chief Financial Officer | Senior Management | 2013 | 66 |
| Jane Chung | Chief Operating Officer; President | Senior Management | 2023 | 53 |
| Anne Borgman, M.D. | Chief Medical Officer | Senior Management | 2023 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer